FCH
CLDX icon

Freestone Capital Holdings’s Celldex Therapeutics CLDX Stock Holding History

Freestone Capital Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-670
Closed -$29K – 337
2017
Q3 		$29K Buy
+670
New +$25.1K ﹤0.01% 339

Other funds holding CLDX

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Freestone Capital Holdings's CLDX Position: Q4 2017 in Review

Freestone Capital Holdings sold out of Celldex Therapeutics (CLDX) in Q4 2017, closing a stake of 670 shares — an estimated $29K sold.

Freestone Capital Holdings first reported a position in CLDX in Q3 2017 and held it in 1 quarter. The position peaked at $29K in Q3 2017. 135 funds tracked by Wall St. Rank hold CLDX as of Q4 2017.

  • Freestone Capital Holdings reported no remaining Celldex Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Freestone Capital Holdings sold 670 Celldex Therapeutics shares in Q4 2017, an estimated $29K.
  • Freestone Capital Holdings first reported a position in Celldex Therapeutics in Q3 2017 and held it in 1 quarter.
  • Freestone Capital Holdings's Celldex Therapeutics position peaked at $29K in Q3 2017.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2017.

Based on Freestone Capital Holdings's 13F filing for Q4 2017, filed 13 Feb 2018.